Control
Sep 30 2022 |
et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.1020123 | Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial |
| 39% higher mortality (p=1), 20% greater improvement (p=0.56), and 16% shorter hospitalization (p=0.07). RCT 60 hospitalized COVID-19 patients showing no significant difference in viral clearance with atovaquone. Patients were randomized 2:1 to receive atovaquone 1500mg BID or placebo for up to 10 days, with both groups receiving standard of.. | ||
Sep 9 2021 |
et al., PLOS Pathogens, doi:10.1371/journal.ppat.1009840 | Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells |
| In Vitro studying identifying 35 compounds that inhibit SARS-CoV-2 in Vero cells and hepatocytes when treated prior to infection, and several compounds that slow replication when treated after infection: vitamin D, amodiaquine, atovaquone.. | ||
Jul 8 2021 |
et al., Journal of Virology & Antiviral Research | Virtual Screening Reveals Potential Anti-Parasitic Drugs Inhibiting the Receptor Binding Domain of SARS-CoV-2 Spike protein |
| In Silico study identifying 32 anti-parisitic compounds effectively inhibiting the RBD of the SARS-CoV-2 spike protein, showing ivermectin and atovaquone among the top compounds. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.